can’t control how the market reacts/values these milestones
but with first dose of VP-001 it’s more likely to reach market than not (grading us based on data set + team, we should be on HD+ grade, market currently valuing us below a pass mark)
the scientific team is lead by Sue F, and with Sri on board - if PYC-001 and PYC-002 milestones are completed timely then the market will be more aware.
I believe the market isn’t aware/have assigned any value to our CNS efforts, at the end of Q3 they will hopefully be very aware via the Q3 call, or earlier via milestone announcement.
Ann: Q3 Investor Call Advance Notice, page-11
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.005(2.44%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $958.2K | 4.847M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 334614 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 379756 | 5 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |